Release Date: August 29, 2025
Expiration Date: August 29, 2026
Activity Overview
Recent practice-changing trial data are poised to change the management of extensive-stage small cell lung cancer (ES-SCLC) substantially. However, new treatment approaches are associated with novel challenges in managing adverse events, which may jeopardize treatment outcomes.
This podcast features a discussion about the appropriate management of adverse events described in recent pivotal trials for regimens used in ES-SCLC management. Led by Rohit Gosain, MD; and Rahul Gosain, MD; this session features a faculty expert in evaluating and treating SCLC.
Target Audience
This educational activity is directed toward medical oncologists, nurse practitioners, physician assistants, and oncology nurses who manage patients with SCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Integrate evolving clinical trial data into patient-centered treatment plans for ES-SCLC
- Identify treatment-related toxicities associated with emerging therapies in SCLC
Rahul Gosain, MD, MBA
Assistant Professor of Clinical Medicine
Medical Director, Wilmot Cancer Institute at Webster
Director, Wilmot Cancer Institute Regional Infusion Services
Wilmot Cancer Institute–Webster
University of Rochester Medicine
Rochester, NY
Disclosures: Consultancy/Advisory: AstraZeneca, Gilead, Janssen Oncology; Honorarium: Cor2ed, Integrity CE, Oncology News Central, SignifyMD
Rohit Gosain, MD
Assistant Professor of Clinical Medicine
University of New York at Buffalo
Director of Roswell Park Care Network Southtowns
Roswell Park Comprehensive Cancer Center
Rochester, NY
Disclosures: Consultancy/Advisory: Eisai; Honorarium: Cor2ed, Integrity CE, Oncology News Central, SignifyMD
Misty D. Shields, MD, PhD
Assistant Professor of Clinical Medicine
Associate Member, Experimental and Developmental Therapeutics
Indiana University School of Medicine
Indianapolis, IN
Disclosures: Advisory Board: AstraZeneca; Speakers’ Bureau: Jazz Pharmaceuticals; Steering Committee: AstraZeneca
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here